Methylphenidate (MPH) is the
first choice pharmacological drug for the treatment of ADHD because of its
well-established activity on hyperactivity and inattention.In child psychiatry,
risperidone (RIS) is beneficial in Disruptive Behaviour Disorders (DBD) and
Pervasive Developmental Disorders (PDD) among other disorders. These medical
indications can effectively treat a number of psychiatric childhood disorders,
but the co-morbid forms are, in some cases, resistant to monotherapy.
Thus, although the
pharmacological action of psychostimulant and antipsychotic drugs may seem to
be the opposite of each other, their combination
may be useful in comorbid forms of ADHD, particularly with Conduct
Disorders (CD) symptoms or disorder, or PDD and DBD.During the last fifteen
years, several publications have reported the benefits observed following
associations between psychostimulant and antipsychotic treatment.
Bitherapies seem well-tolerated,
and beneficial effects have been even found on appetite and sleep disturbances.
However, the offsetting effect of adverse effects are not always obvious and
the most recent results show that the psychostimulant does not reduce the
effects of antipsychotic medication on sedation, weight and body mass index,
metabolic parameters and prolactin levels.
No comments:
Post a Comment